Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Septic shock is a common syndrome caused by the body's response to an infection. Septic shock
is responsible for 10% of all ICU admissions and 30% of ICU deaths. Use of "beta blocker"
medications may improve outcomes after septic shock. This pilot study evaluates protocols to
infuse the beta blocker esmolol in patients with septic shock.